The impact of proton pump inhibitors on the intestinal microbiota in chronic hepatitis C patients

Literature

• Farrell B, Pottie K, Thompson W, et al. Deprescribing proton pump inhibitors: evidence-based clinical practice guideline. Can Fam Physician. 2017;63:354–364.
   PubMed Web of Science ®Google Scholar
• Yang J-C, Lu C-W, Lin C-J. Treatment of Helicobacter pylori infection: current status and future concepts. World J Gastroenterol. 2014;20:5283.
   PubMed Web of Science ®Google Scholar
• Kelly OB, Dillane C, Patchett SE, et al. The inappropriate prescription of oral proton pump inhibitors in the hospital setting: a prospective cross-sectional study. Dig Dis Sci. 2015;60:2280–2286.
   PubMed Web of Science ®Google Scholar
• Boardman HF, Heeley G. The role of the pharmacist in the selection and use of over-the-counter proton-pump inhibitors. Int J Clin Pharm. 2015;37:709–716.
   PubMed Web of Science ®Google Scholar
• Angeli P, Bernardi M, Villanueva C, et al. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69:406–460.
   PubMed Web of Science ®Google Scholar
• Piano S, Brocca A, Mareso S, et al. Infections complicating cirrhosis. Liver Int. 2018;38:126–133.
   PubMed Web of Science ®Google Scholar
• Lata J, Stiburek O, Kopacova M. Spontaneous bacterial peritonitis: a severe complication of liver cirrhosis. World J Gastroenterol. 2009;15:5505.
   PubMed Web of Science ®Google Scholar
• Dever JB, Sheikh MY. Review article: spontaneous bacterial peritonitis – bacteriology, diagnosis, treatment, risk factors and prevention. Aliment Pharmacol Ther. 2015;41:1116–1131.
   PubMed Web of Science ®Google Scholar
• Imhann F, Bonder MJ, Vila AV, et al. Original article: proton pump inhibitors affect the gut microbiome. Gut. 2016;65:740.
   PubMed Web of Science ®Google Scholar
• Clooney AG, Bernstein CN, Leslie WD, et al. A comparison of the gut microbiome between long‐term users and non‐users of proton pump inhibitors. Aliment Pharmacol Ther. 2016;43:974–984.
   PubMed Web of Science ®Google Scholar
• Tsuda A, Suda W, Morita H, et al. Influence of proton-pump inhibitors on the luminal microbiota in the gastrointestinal tract. Clin Transl Gastroenterol. 2015;6:e89.
   PubMed Web of Science ®Google Scholar
• Takagi T, Naito Y, Inoue R, et al. The influence of long-term use of proton pump inhibitors on the gut microbiota: an age-sex-matched case-control study. J Clin Biochem Nutr. 2018;62:100.
   PubMed Web of Science ®Google Scholar
• Naito Y, Kashiwagi K, Takagi T, et al. Intestinal dysbiosis secondary to proton-pump inhibitor use. Digestion. 2018;97:195–204.
   PubMed Web of Science ®Google Scholar
• Bajaj JS, Acharya C, Fagan A, et al. Proton pump inhibitor initiation and withdrawal affects gut microbiota and readmission risk in cirrhosis. Am J Gastroenterol. 2018;113:1177–1186.
   PubMed Web of Science ®Google Scholar
• Freedberg DE, Lebwohl B, Abrams JA. The impact of proton pump inhibitors on the human gastrointestinal microbiome. Clin Lab Med. 2014;34:771.
   PubMed Web of Science ®Google Scholar
• Barletta JF, El-Ibiary SY, Davis LE, et al. Proton pump inhibitors and the risk for hospital-acquired Clostridium difficile infection. Mayo Clin Proc. 2013;88:1085–1090.
   PubMed Web of Science ®Google Scholar
• Jackson MA, Goodrich JK, Maxan M-E, et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut. 2016;65:749–756.
   PubMed Web of Science ®Google Scholar
• Bajaj JS, Cox IJ, Betrapally NS, et al. Innovative and emerging technologies in GI physiology and disease: systems biology analysis of omeprazole therapy in cirrhosis demonstrates significant shifts in gut microbiota composition and function. Am J Physiol - Gastrointest Liver Physiol. 2014;307:G951.
   PubMed Web of Science ®Google Scholar
• Merli M, Lucidi C, Gregorio VD, et al. The chronic use of beta‐blockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis. Liver Int. 2015;35:362–369.
   PubMed Web of Science ®Google Scholar
• Heidrich B, Vital M, Plumeier I, et al. Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls. Liver Int. 2018;38:50–58.
   PubMed Web of Science ®Google Scholar
• Inoue T, Nakayama J, Moriya K, et al. Gut dysbiosis associated with hepatitis C virus infection. Clin Infect Dis. 2018;67:869–877.
   PubMed Web of Science ®Google Scholar
• Tergast TL, Wranke A, Laser H, et al. Dose‐dependent impact of proton pump inhibitors on the clinical course of spontaneous bacterial peritonitis. Liver Int. 2018;38:1602–1613.
   PubMed Web of Science ®Google Scholar
• Cole JR, Wang Q, Fish JA, et al. Ribosomal database project: data and tools for high throughput rRNA analysis. Nucl Acids Res. 2014;42:D633–D642.
   PubMed Web of Science ®Google Scholar
• Wang Q, Garrity GM, Tiedje JM, et al. Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl Environ Microbiol. 2007;73:5261–5267.
   PubMed Web of Science ®Google Scholar
• Tsochatzis EA, Gurusamy KS, Ntaoula S, et al. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol. 2011;54:650–659.
   PubMed Web of Science ®Google Scholar
• Friedrich-Rust M, Wunder K, Kriener S, et al. Liver fibrosis in viral hepatitis: noninvasive assessment with acoustic radiation force impulse imaging versus transient elastography. Radiology. 2009;252:595–604.
   PubMed Web of Science ®Google Scholar
• Heidrich B, Cordes H-J, Klinker H, et al. Treatment extension of pegylated interferon alpha and ribavirin does not improve SVR in patients with genotypes 2/3 without rapid virological response (OPTEX Trial): a prospective, randomized, two-arm, multicentre phase IV clinical trial. Su C-W, ed. PLoS One. 2015;10:e0128069.
   PubMed Web of Science ®Google Scholar
• Clarke KR, Gorley RN. PRIMER v7: user manual/tutorial. Plymouth: PRIMER-E, 2015. 296 p.
   Google Scholar
• McMurdie PJ, Phyloseq HS. A bioconductor package for handling and alalysis of high-throughput phylogenetic sequence data. Pac Symp Biocomput. 2011;17:235–246.
   Google Scholar
• Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.
   PubMed Web of Science ®Google Scholar
• Fujimori S. What are the effects of proton pump inhibitors on the small intestine? World J Gastroenterol. 2015;21:6817–6819.
   PubMed Web of Science ®Google Scholar
• Su T, Lai S, Lee A, et al. Meta-analysis: proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth. J Gastroenterol. 2018;53:27–36.
   PubMed Web of Science ®Google Scholar
• Lo W, Chan WW. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol. 2013;11:483–490.
   PubMed Web of Science ®Google Scholar
• Mokany K, Harwood TD, Overton JM, et al. Combining α ‐ and β ‐diversity models to fill gaps in our knowledge of biodiversity. Ecol Lett. 2011;14:1043–1051.
   PubMed Web of Science ®Google Scholar
• The Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature. 2012;486:207–214.
   PubMed Web of Science ®Google Scholar
• Le Chatelier E, Nielsen T, Qin J, MetaHIT consortium, et al. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013;500:541–546.
   PubMed Web of Science ®Google Scholar
• Le Bastard Q, Al ‐Ghalith GA, Gregoire M, et al. Systematic review: human gut dysbiosis induced by non‐antibiotic prescription medications. Aliment Pharmacol Ther. 2018;47:332–345.
   PubMed Web of Science ®Google Scholar
• Bajaj JS, Heuman DM, Hylemon PB, et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol. 2014;60:940–947.
   PubMed Web of Science ®Google Scholar
• O’Leary JG, Reddy KR, Wong F, et al. Long-term use of antibiotics and proton pump inhibitors predict development of infections in patients with cirrhosis. Clin Gastroenterol Hepatol. 2015;13:753–759.e1-2.
   PubMed Web of Science ®Google Scholar
• Dam G, Vilstrup H, Watson H, et al. Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites. Hepatology 2016;64:1265–1272.
   PubMed Web of Science ®Google Scholar
• Pericleous M, Sarnowski A, Moore A, et al. The clinical management of abdominal ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: a review of current guidelines and recommendations. Eur J Gastroenterol Hepatol. 2016;28:e10–e18.
   PubMed Web of Science ®Google Scholar
• Preto-Zamperlini M, Farhat SCL, Perondi MBM, et al. Elevated C-reactive protein and spontaneous bacterial peritonitis in children with chronic liver disease and ascites. J Pediatr Gastroenterol Nutr. 2014;58:96–98.
   PubMed Web of Science ®Google Scholar